Optic neuritis

Rewind Therapeutics Appoints Dr. Stephen Burbidge to its Management Team

Retrieved on: 
星期二, 十一月 29, 2022
GlaxoSmithKline, Doctor of Philosophy, Rewind, GSK, Remyelination, Head, Demyelinating disease, University, Therapy, Bachelor of Science, Patient, Neuroscience, Molecular genetics, Discovery, Optic neuritis, Consultant, PMV, Nerve injury, Biology, Multiple sclerosis, University of Warwick, Roche, Ludwig Cancer Research, Total survey error, Drug discovery, HIV disease progression rates, Medical device, Pharmaceutical industry, Research

Leuven, Belgium, November 29, 2022 --- Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated diseases, today announced that Dr. Stephen Burbidge has been appointed to the Company´s management team as Head of Research and Discovery.

Key Points: 
  • Leuven, Belgium, November 29, 2022 --- Rewind Therapeutics , a company developing first-in-class treatments for demyelination-associated diseases, today announced that Dr. Stephen Burbidge has been appointed to the Companys management team as Head of Research and Discovery.
  • "We are delighted to welcome Stephen Burbidge at Rewind Therapeutics," said Anja Harmeier, Chief Executive Officer at Rewind Therapeutics.
  • "Rewind Therapeutics is focusing on remyelination therapies, an area of increasing importance in treating neurological and nerve-related diseases," said Dr. Stephen Burbidge.
  • Rewinds team has extensive R&D expertise and has built a strong patent estate for developing novel remyelination therapeutics.

Rewind Therapeutics Appoints Irene Knuesel, PhD, as Chief Scientific Officer

Retrieved on: 
星期三, 十月 19, 2022
Rewind, Nerve injury, Disease, Therapy, CSO, PD, Swiss Federal Institute of Aquatic Science and Technology, Science, Multiple sclerosis, Optic neuritis, Patient, Total survey error, Research, HIV disease progression rates, University, Company, Drug discovery, Doctor of Philosophy, Industry, Remyelination, CNS, Demyelinating disease, Head, University of Zurich, California Institute for Quantitative Biosciences, Swiss Federal Institute of Technology, Molecular neuroscience, Neurodegeneration, PMV, Pharmaceutical industry

Leuven, Belgium, October 19, 2022 --- Rewind Therapeutics, a company developing first-in-class treatments for demyelination-associated diseases, today announced that Irene Knuesel, PhD, PD, has been appointed as the Company´s Chief Scientific Officer.

Key Points: 
  • Leuven, Belgium, October 19, 2022 --- Rewind Therapeutics , a company developing first-in-class treatments for demyelination-associated diseases, today announced that Irene Knuesel, PhD, PD, has been appointed as the Companys Chief Scientific Officer.
  • "We warmly welcome Irene as our new CSO and are excited that she joins Rewind," said Anja Harmeier, Chief Executive Officer at Rewind Therapeutics.
  • Our goal is to progress to a clinical-stage portfolio company and we know Irene will play a significant role in advancing Rewind."
  • "Rewind Therapeutics has built a great team and comprehensive expertise in remyelination," said Irene Knuesel, Chief Scientific Officer at Rewind Therapeutics.

Trethera Announces Multiple Sclerosis Treatment Poster Presentation at the American Neurological Association Annual Meeting

Retrieved on: 
星期二, 十月 4, 2022
Orphan drug, ANA, Cancer, GLOBE, Acute disseminated encephalomyelitis, Optic nerve, American Neurological Association, Immunology, Adult, Nucleotide, MS, EAE, Research, Private Securities Litigation Reform Act, DCK, Deoxycytidine kinase, FDA, University of California, Los Angeles, Autoimmunity, COVID-19, Visual impairment, UCLA, Lists of diseases, ADEM, Degenerative disease, Patient, Multiple sclerosis, Optic neuritis, Central nervous system, University, DNA, Company, Pharmaceutical industry

LOS ANGELES, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (Trethera), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announces an upcoming poster presentation at the 147th Annual Meeting of the American Neurological Association (ANA).

Key Points: 
  • LOS ANGELES, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (Trethera), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announces an upcoming poster presentation at the 147th Annual Meeting of the American Neurological Association (ANA).
  • The ANA meeting is one of the largest annual gatherings of MS researchers and a key venue for presenting noteworthy neurology discoveries.
  • The work presented by Dr. Clark also has application for optic neuritis, a rare neurologic disease which affects the optic nerve causing visual impairment.
  • TRE-515 is an orally delivered first-in-class therapeutic engineered to inhibit dCK, the key enzyme in the nucleoside salvage pathway.

Global Optic Neuritis Treatment Market to Grow at a 4.1% CAGR Through 2027 - ResearchAndMarkets.com

Retrieved on: 
星期五, 九月 16, 2022
Optical, Health, COVID-19, Inflammation, Multiple sclerosis, Incidence, Journal, COVID-19, Woman, Optic neuritis, Brain, Prevalence, Sclerosis, Population, Journal of Neurologic Physical Therapy, Neuritis, Severe cognitive impairment, Eye, Steroid, Pain, Optic nerve, Awareness, Neurology, Color, Disease, Field line, CAGR, Telescopic sight, Dietary supplement, Medical imaging, Growth

The "Optic Neuritis Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Optic Neuritis Treatment Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)" report has been added to ResearchAndMarkets.com's offering.
  • The optic neuritis treatment market is expected to register a CAGR of 4.1% during the forecast period.
  • Rise in the geriatric population, increasing incidence of multiple sclerosis, and growing awareness about early detection of optic neuritis are the key driving factors of the optic neuritis treatment market.
  • According to the Optic Neuritis Foundation Inc, adults between the ages of 18-45 years are most prone to optic neuritis.

Trethera and UCLA Publish Data Demonstrating TRE-515 Ability to Control and Improve Multiple Sclerosis Symptoms in Mouse Models

Retrieved on: 
星期三, 九月 7, 2022
Molecular imaging, PET, ADEM, Cancer, Research, Time of flight, Degenerative disease, Brain, Deoxycytidine kinase, Science, Multiple sclerosis, DCK, CyTOF, Pediatrics, DNA, EAE, Orphan drug, National, Immunology, GLOBE, National academy, Cytometry, Company, FDA, Stanford University, UCLA, MS, COVID-19, Optic neuritis, Private Securities Litigation Reform Act, Patient, Pharmaceutical industry, Medical imaging

TRE-515 is a clinical stage drug being developed by Trethera that targets the enzyme deoxycytidine kinase (dCK) in the deoxyribonucleoside salvage pathway.

Key Points: 
  • TRE-515 is a clinical stage drug being developed by Trethera that targets the enzyme deoxycytidine kinase (dCK) in the deoxyribonucleoside salvage pathway.
  • Their results demonstrated that dCK activity is necessary for the development of clinical symptoms in both EAE models of MS.
  • Targeting dCK with TRE-515 limited disease severity when treatments were started prophylactically at disease induction or therapeutically after symptoms appear.
  • (2022), Targeting deoxycytidine kinase improves symptoms in mouse models of multiple sclerosis.

Sinomab Announces IND Application of SN1011 for the Treatment of Neuromyelitis Optica Spectrum Disorder Approved by NMPA

Retrieved on: 
星期三, 八月 24, 2022
Ibrutinib, Investigational New Drug, The Company, Rheumatoid arthritis, Safety, CD22, Research, RA, Central nervous system, Degenerative disease, IND, Smoking, SLE, Mab, Disease, EBV, Multiple sclerosis, Epstein–Barr virus infection, R, National Medical Products Administration, Thirteenth, Asthma, B-cell lymphoma, Twelfth, NHL, NMPA, Antibody, Non-Hodgkin lymphoma, Neuromyelitis optica spectrum disorder, Company, Therapy, Lupus, PV, NMOSD, The Group, MS, Optic nerve, Optic neuritis, Spinal cord, Drug discovery, SM03, BTK, Trial of the century, Pemphigus, Pharmaceutical industry, Phase

The IND approval would enable the Company to initiate the Phase II/III clinical study in China to evaluate the efficacy and safety of SN1011 for the treatment of NMOSD in China.

Key Points: 
  • The IND approval would enable the Company to initiate the Phase II/III clinical study in China to evaluate the efficacy and safety of SN1011 for the treatment of NMOSD in China.
  • SN1011 differentiates from existing BTK inhibitors currently available in the market, such as Ibrutinib, in terms of mechanism of action, affinity, selectivity and safety.
  • Currently, four IND applications of SN1011 for the treatment of SLE, PV, MS and NMOSD have been approved by NMPA respectively.
  • SinoMab BioScience Limited (stock code: 3681.HK) is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases.

Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 for the Treatment of Demyelinating Optic Neuritis

Retrieved on: 
星期二, 八月 9, 2022
FDA, Death, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Mouse, Inflammation, CEO, MS, GLOBE, Private Securities Litigation Reform Act, Cancer, UCLA, Optic neuritis, ADEM, Disease, Research, CNS demyelinating autoimmune diseases, Pain, Steroid, Marketing, Patient, Deoxycytidine kinase, DNA, Multiple sclerosis, Company, Orphan drug, Autoimmune disease, Severe cognitive impairment, Central nervous system, ODS, DCK, COVID-19, Optic nerve, Degenerative disease, Food, Immune system, Association, Acute disseminated encephalomyelitis, Pharmaceutical industry, Medical device

LOS ANGELES, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (Trethera), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Status (ODS) to TRE-515 for the treatment of optic neuritis (ON).

Key Points: 
  • LOS ANGELES, Aug. 09, 2022 (GLOBE NEWSWIRE) -- Trethera Corporation (Trethera), a clinical stage biopharmaceutical company committed to developing novel drugs targeting nucleotide metabolism for the treatment of cancer and autoimmune diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Status (ODS) to TRE-515 for the treatment of optic neuritis (ON).
  • TRE-515 is developing an impressive resume for potential treatments of demyelinating autoimmune diseases.
  • The ODS designation qualifies Trethera for certain incentives, which include FDA assistance in designing clinical trials, access to the FDA Orphan Drug Grants Program, exemption from the drug approval application fee and eligibility for seven years of marketing exclusivity.
  • Trethera's innovative approach to targeting nucleotide metabolism led to the development of TRE-515, an orally taken capsule twice designated by the FDA as an Orphan Drug.

Bioasis Acquires Phase 2 Ready Rare Orphan EGF Assets

Retrieved on: 
星期四, 六月 16, 2022
Multiple sclerosis, Optic neuritis, Neuroinflammation, FDA, Therapy, EGF, TSX, Traffic barrier, Technology, Achievement, Sellers, Company, Biotechnology, Guillain–Barré syndrome, Director, Human, Peptide, Disease, Central nervous system, IND, Epidermal growth factor, Neurodegeneration, TSX Venture Exchange, Board, Neurology, GLOBE, Pharmaceutical industry, Holding company

NEW HAVEN, Conn., U.S.A., June 16, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”) a biopharmaceutical company developing its proprietary xB3TM platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”) announced today that it has entered into an asset purchase agreement with the owners (the “Sellers”) of Cresence AS of Oslo, Norway.

Key Points: 
  • This transaction is transformational for Bioasis, bringing Phase 2 ready assets aligned with our focus in rare disease and orphan drug indications.
  • The transfer of these assets to Bioasis will speed up the development of EGF therapeutics for the treatment of certain rare neurodegenerative disorders, Professor Francois Curtin, co-founder and Vice-Chairman of the Cresence Board observed.
  • In addition, the combination of Bioasis xB3TM platform with our EGF technology is anticipated to improve the brain delivery of our neurotherapeutic molecules, he added.
  • The addition of this key intellectual property provides Bioasis a Phase 2 clinical stage ready molecule that is synergistic with Bioasis existing technology and therapeutic areas of interest.

SinoMab Announces IND APPLICATION FOR SN1011 ACCEPTED BY NMPA CDE

Retrieved on: 
星期四, 六月 9, 2022
The Company, National Medical Products Administration, Degenerative disease, CDE, Company, Neuromyelitis optica spectrum disorder, Pemphigus vulgaris, Lupus, Research, NHL, Mab, Drug discovery, Safety, CD22, Epstein–Barr virus infection, SM03, RA, SLE, Central nervous system, Optic neuritis, Disease, Smoking, Center, Investigational New Drug, IND, Therapy, Optic nerve, NMPA, Spinal cord, Twelfth, PV, Thirteenth, Patient, MS, BTK, Rheumatoid arthritis, Incidence, Antibody, Union, IL-6, Multiple sclerosis, US, The Group, Center for Drug Evaluation and Research, EBV, Asthma, NMOSD, B-cell lymphoma, Recurrence, Pharmaceutical industry, Pemphigus, Phase

The Company plans to initiate the Phase II clinical study in China upon approval of the present IND.

Key Points: 
  • The Company plans to initiate the Phase II clinical study in China upon approval of the present IND.
  • The present IND submission, once granted, will enable the Company to conduct clinical program in China for treatment of NMOSD.
  • SN1011 differentiates from existing BTK inhibitors currently available in the market in terms of mechanism of action, affinity, selectivity and safety.
  • An IND application for NMOSD for SN1011 of SinoMab has been accepted by the CDE of the NMPA, and once approved, will facilitate the clinical research and development of new drugs for NMOSD in China.

SATT[1] Conectus and Find Therapeutics Sign Licensing Agreement to Develop a Promising New Therapy for Multiple Sclerosis and other demyelinating diseases

Retrieved on: 
星期二, 六月 7, 2022
People, Multiple Sclerosis Society, Eye, IMS, Program, Research, THE, Institute, Multiple sclerosis, Degenerative disease, Central nervous system, Nerve Damage, Laboratory, AND, Inflammation, CEO, Neuron, Neuroprotection, Disease, Regeneration, Investment, Optic neuritis, Therapy, Patient, MS, ADMAR, Multiple Sclerosis Society of Canada, Immune system, Remyelination, Autoimmune disease, Quality of life, Technology transfer, Inserm, Industry, Drug design, University of Strasbourg, Element, Find, Pharmaceutical industry, Medical device

Promising preclinical data show that this innovative therapy, by overcoming the molecular barriers of myelin regeneration, could restore myelin function.

Key Points: 
  • Promising preclinical data show that this innovative therapy, by overcoming the molecular barriers of myelin regeneration, could restore myelin function.
  • According to the Multiple Sclerosis Society of Canada, Canada has one of the highest MS rates in the world with 1 in every 400 people affected.
  • Initial preclinical pharmacology studies, funded by SATT Conectus, have demonstrated very encouraging results, delivering increased myelin and better function after treatment.
  • Find Therapeutics, is dedicated to the development of next generation trans-membrane allosteric modulators to treat rare and inflammatory diseases.